Altered MHC class I antigens in tumors

International Journal of Clinical and Laboratory Research

Volumn 27, Issue 2, 1997, Pages 95-102

  Algarra, I ^a   Collado, A ^a   Garrido, F ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

Author keywords

Escape; H 2; HLA; MHC; Tumor phenotypes

Indexed keywords

ANIMALIA;

EID: 0030749146     PISSN: 09405437     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02912442     Document Type: Review

References (63)

1. Garrido F, Festenstein H, Schirrmacher V. Further evidence for derepression of H-2 and Ia like specificities of foreign haplotypes in mouse tumour cell lines. Nature 1976; 261:705.
2. Garrido F, Festenstein H. Expression of H-2K, H-2D and Ia region products of foreign haplotypes on mouse tumour cells. Folia Biol (Praha) 1976; 1:391.
3. d sarcoma. J Immunogenet 1979; 6:83.
4. Townsend A, Rothbard J, Gotch FM, Bahadur G, Wraith D, McMichael AJ. The epitopes of influenza cleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 1986; 44:959.
5. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. Structure of the human class I histocompatibility antigen, HLA-A2. Nature 1987; 329:506.
6. Mornburg F, Neefjes JJ, Hämmerling GJ. Peptide selection by MHC-encoded TAP transporters. Curr Opin Immunol 1994; 6:32.
7. Festenstein H, Garrido F. MHC antigens and malignancy. Nature 1986; 3220:502.
8. Festenstein H, Schmidt W. Variation in MHC antigenic profiles of tumor cells and its biological effects. Immunol Rev 1981; 60:85.
9. Kaklamanlis L, Hill A. MHC loss in colorectal tumours: evidence for immunoselection? Cancer Surv 1992; 13:155.
10. Hui K, Grosveld F, Festenstein H. Rejection of transplantable AKR leukaemia following MHC DNA-mediated cell transformation. Nature 1984; 311:750.
11. Tanaka K, Isselbacher KJ, Khoury G, Jay G. Reversal of oncogenesis by the expression of a major histocompatibility complex class I gene. Science 1985; 228:26.
12. Mialdea MJ, Gaforio JJ, Pérez M, Garrido F Effect of MHC class I transfection on local tumor growth and metastasis capacity in a H-2 negative clone of a chemically induced fibrosarcoma. Int J Cancer 1992;52:153.
13. Pollack MS, Livingston PO, Fogh J, Carey TE, Oettgen HF, Dupont SO. Genetically appropriate expression of HLA and DR (IA) alloantigens on human melanoma cell lines. Tissue Antigens 1980; 15:249.
14. Csiba A, Whitwell HL, Moore M. Distribution of histocompatibility and leucocyte differentiation antigens in normal human colon and in benign and malignant colonie neoplasms. Br J Cancer 1984; 50:699
15. López Nevot MA, García E, Pareja E, Bonal FJ, Martín J, Ruiz-Cabello F, Garrido F. Differential expression of HLA class I and II antigens between primary and metastatic melanomas. J Im-munogenet 1986; 130: 219.
16. Löpez Nevot MA, Esteban F, Ferron A, Gutierrez J, Oliva MR, Romero C, Huelin C, Ruiz-Cabello F, Garrido F. HLA class I gene expression on human primary tumours and autologous metastasis: demonstration of selective losses of HLA antigens on colorectal, gastric and laryngeal carcinomas. Br J Cancer 1989; 59:221.
17. Garrido F, Klein E. MHC antigen expression I. Human tumors. Semin Cancer Biol 1991;2:1.
18. Garrido F. The biological implications of the abnormal expression of histocompatibility antigens on murine and human tumors. In: David C, ed. Gene complex, genes, molecules, function. Bar Harbor, Maine: Plenum 1987: Nato ASI series, 144:623.
19. Moretta A, Bottino C, Vitale M, Pende D, Biassoni R, Mingari MC, Moreita L. Receptors for HLA class-I molecules in human natural killer cells. Annu Rev Immunol 1996; 14:619.
20. Gumperz J, Parham P. The enigma of the natural killer cell. Nature 1995; 378:245.
21. Lanier LL, Phillips JH. Inhibitory MHC class I receptors on NK cells and T cells. Immunol Today 1996; 17:86.
22. Garrido F, Schirrmacher V, Festenstein H. Studies on H-2 specificities on mouse tumour cells by a new microradioassay. J Immunogenet 1977;4:15.
23. Perez M, Garrido A, Algarra I, Garrido F. Different H-2 phenotypes in clones derived from a new B ALB/c solid tumor. Its relevance for local tumor growth. Immunologia 1985; 4:60.
24. Perez M, Garrido A, Algarra I, Caballero A, Delgado C, Collado MD, Fernandez Cruz E, Garrido F. H-2 antigens and tumor-associated transplantation antigens in clones derived from a methylcholanthrene-induced BALB/c tumor: their influence on the generation in vitro and in vivo of the specific anti-tumor immune response. Exp Clin Immunogenet 1989; 6:204
25. Algarra I, Gaforio JJ, Garrido A, Mialdea MJ, Perez M, Garrido F. Heterogeneity of MHC-class I antigens in clones of methylcholanthrene-induced tumors. Implications for local growth and metastasis. Int J Cancer 1991; 6 [Suppl]: 73.
26. Algarra I, Öhlen C, Perez M, Ljunggren HG, Klein G, Garrido F, Kärre K. NK sensitivity and lung clearance of MHC-class I-deficient cells within a heterogeneous fibrosarcoma. Int J Cancer 1989; 44:675.
27. Van Waes C, Monach PA, Urban JL, Wortzel RD, Schreiber H. Immunodominance deters the response to other tumor antigens thereby favoring escape: prevention by vaccination with tumor variants selected with cloned cytolytic T cells in vitro. Tissue Antigens 1996; 47:399.
28. Eisenbach L, Hollander N, Greenfeld L, Yakor H, Segal S, Feldman M. The differential expression of H-2K versus H-2D antigens, distinguishing high-metastatic from low-metastatic clones, is correlated with the immunogenic properties of the tumor cells. Int J Cancer 1984; 34:567.
29. Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, Duggan-Keen M, Stern PL. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today. 1997; 18,2:89.
30. Katzav S, De Baetselier P, Tartakousky B, Feldman M, Segal S. Alteration in major histocompatibility complex phenotypes of mouse cloned T10 sarcoma cells: association with shifts from non-metastatic to metastatic cells. 1983; 71:317.
31. Garrido F. HLA and cancer. Tissue antigens 1996, 47:361.
32. Garrido F, Cabrera T, Concha A, Glew S, Ruiz-Cabello F, Stern PL. Natural history of HLA expression during tumor develop-ment. Immunol Today 1993; 10:491.
33. Garrido F, Cabrera T, Lopez Nevot MA, Ruiz-Cabello F. HLA class I antigens inhuman tumors. Adv Cancer Res 1995;67:155.
34. Garrido F, Cabrera T, Accola RS, Bensa JC, Bodmer W, Dohr G, Drenou B, Drouet M, Fauchet R, Ferrara GB, Ferrone S, Giacomini P, Kageshita T, Koopman L, Maio M, Marincola F, Mazzilli C, Morel PA, Murray A, Papasteriades C, Salvaneschi L, Stern PL, Ziegler A. HLA and cancer. In: Charron D, ed. HLA. Genetic diversity of HLA. Functional and medical implications. Sèvres, France: EDK; 1997; (in press).
35. Lehmann F, Marchand M, Hainaut P, Pouillart P, Sastre X, Ikeda H, Boon T, Coulie PG. Differences in the antigen recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol 1995; 25: 340.
36. Alberti S, Herzenberg LA, DNA methylation prevents transfection of genes for specific surface antigens. Proc Natl Acad Sci USA 1988; 85:8391.
37. Maschek U, Pulm W, Segal S, Hammerimg GJ. Major histocompatibility complex class I genes in murine fibrosarcoma IC9 are down regulated at the level of the chromatin structure. Mol Cell Biol 1989;9:3136.
38. Boucraut J, Guillaudeux T, Alizadeh M, Boretto J, Chimim G, Malecaze F, Semana G, Fauchet R, Pontarotti P, Le Bouteiller P. HLA-E is the only class I gene that escapes CpG methylation and is transcriptionally active in the trophoblast-derived human cell line JAR. Immunogenetics 1993; 38:117.
39. Henseling U, Schmidt W, Scholler HR, Gruss P, Hatzopoulos AK. A transcription factor interacting with the class I gene enhancer is inactive in tumorigenic cell lines which suppress major histocompatibility complex class I genes. Mol Cell Biol 1990; 10:4100.
40. Blanchet O, Bourge JF, Zinszner H, Tatari Z, Degos L, Paul P. DNA binding of regulatory factors interacting with MHC-class-I gene enhancer correlates with MHC-class-I transcriptional level in class-I-defective cell lines. Int J Cancer 1991; [Suppl]6:138.
41. Blanchet O, Bourge JF, Zinszner H, Israel A, Kourilsky P, Dausset J, Degos L, Paul P. HLA class I enhancer sequence in human tumor cell lines lacking class I antigen expression. Proc Natl Acad Sci USA 1992; 89:3488.
42. Van't Verr LJ, Beijersbergen RL, Bernards R. N-myc suppresses major histocompatibility complex class I gene expression through down-regulation of the p50 subunit of NF-kappa B. EMBO J 1993; 12:195.
43. Liu X, Ge R, Westmoreland S, Cooney AJ, Tsai SY, Tsai MJ, Ricciardi RP. Negative regulation by the R2 element of the MHC class I enhancer in adenovirus-12 transformed cells correlates with high levels of COUP-TF binding. Oncogene 1994; 9:2183.
44. Ge R, Liu X, Ricciardi RP. EIA oncogene of adenovirus-12 mediates trans-repression of MHC class I transcription in Ad5/Ad12 somatic hybrid transformed cells. Virology 1994; 203:389.
45. Howcroft TK, Richardon JC, Singer DS. MHC class I gene expression is negatively regulated by the proto-oncogene, c-jun. EMBO J 1993; 12:3163.
46. Versteeg R, Noordermeer IA, Krüse-Wolters M, Ruiter DJ, Schrier PI, c-myc down-regulates class I HLA expression in human melanomas. EMBO J. 1988, 7:1023.
47. Marincola FM, Shamamian P, Alexander RB, Gnarra JR, Turetskaya RL, Nedospasov SA, Simonis TB, Taubenberger JK, Yannelli J, Mixon A, Restifo NP, Herlyn M, Rosenberg SA. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. J Immunol 1990; 153:1225.
48. Torres MJ, Ruiz-Cabello F, Skoudy A, Berrozpe G, Jimenez P, Serrano A, Real FX, Garrido F. Loss of an HLA haplotype in pancreas cancer tissue and its corresponding tumor derived cell line. Tissue Antigens 1996; 47:372.
49. Andersson M, Paabo S, Nilsson T, Peterson PA. Impaired intracellular transport of class I MHC antigens as a possible means for adenoviruses to evade immune surveillance. Cell 1985; 43:215.
50. Korner H, Burgert HG. Down-regulation of HLA antigens by the adenovirus type 2 E3/19K protein a T lymphoma cell line. J Virol 1994; 68:1442.
51. Hill AB, Barnett BC, McMichael AJ, McGeoch DJ. HLA class I molecules are not transported to the cell surface in cells infected with herpes simplex virus types 1 and 2. J Immunol 1994; 152: 2736.
52. Beersma MF, Bijlmakers MJ, Ploegh HL. Human cytomegalovirus down-regulates HLA class I expression by reducing the stability of class I H chains. J Immunol 1993; 151:4455.
53. Rosa F, Berissi H, Weissenbach J, Maroteaux L, Fellous M, Revel M. The B2-microglobulin mRNA in human Daudi cells has a mutated initiation codon but is still inducible by interferons. EMBO J 1983; 2:239.
54. D'Urso CM, Wang ZG, Cao Y, Tatake R, Zeff RA, Ferrone S. Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression. J Clin Invest 1991; 87:284.
55. Bicknell DC, Rowan A, Bodmer WF. Beta2-microglobulin gene mutations: a study of established colorectal cell lines and fresh tumors. Proc Natl Acad Sci USA 1994; 91:4751.
56. Restifo NP, Esquivel F, Kawakami Y, Yewdell JW, Mule JJ, Rosenberg SA, Bennink JR. Identification of human cancers deficient in antigen processing. J Exp Med 1993; 177:265.
57. Cromme FV, Bommel PF van, Walboomers JM, Gallee MP, Stern PL, Kenemans P, Helmerhorst TJ, Stukart MJ, Meijer CJ. Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours. Br J Cancer 1994;69:1176.
58. Cromme FV, Airey J, Heeemels MT, Ploegh HL, Keating PJ, Stern PL, Meijer CJLM, Walboomers JMM Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J Exp Med 1994; 179:335.
59. Townsed A, Bodmer H. Antigen recognition by class I-restricted T lymphocytes. Annu Rev Immunol 1989; 7:601.
60. DeMars R, Rudersdorf R, Chang C, Petersen J, Strandtmann J, Korn N, Sidwell B, Orr HT. Mutations that impair a posttranscriptional step in expression of HLA-A and B antigens. Proc Natl Acad Sci USA 1985; 82:8183.
61. Hosken NA, Bevan MJ. Defective presentation of endogenous antigen by a cell line expressing class I molecules. Science 1990; 248:367.
62. Cerundolo V, Alexander J, Anderson K, Lamb C, Cresswell A, McMichael A, Gotch F, Townsend A. Presentation of viral antigen controlled by a gene in the major histocompatibility complex. Nature 1990; 345:449.
63. Spies T, DeMars R. Restored expression of major histocompat-ibility molecules by gene transfer putative peptide transporter. Nature 1991; 351:323.